These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1768632)

  • 1. Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group.
    Schwartsmann G; Medina de Cunha F; Silveira LA; Salgado G; Thereza MS; Vinholes J; Preger P; Segal F
    Ann Oncol; 1991 Jun; 2(6):443. PubMed ID: 1768632
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma.
    Jekunen A; Stengård J; Pyrhönen S
    Eur J Cancer; 1994; 30A(2):245. PubMed ID: 8155397
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB).
    Sorio R; Galligioni E; Crivellari D; Talamini R; Monfardini S
    Ann Oncol; 1995 Mar; 6(3):306-7. PubMed ID: 7612500
    [No Abstract]   [Full Text] [Related]  

  • 4. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
    Liu JH; Yang MH; Fan FS; Yen CC; Wang WS; Chang YH; Chen KK; Chen PM
    Urology; 2001 Apr; 57(4):650-4. PubMed ID: 11306370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone.
    Merimsky O; Chaitchik S
    Eur J Cancer; 1990; 26(8):921. PubMed ID: 2145941
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined interferon and vinblastine treatment in advanced renal cell cancer.
    Kellokumpu-Lehtinen P; Jantunen I; Flander M; Johansson R; Nordman E
    Acta Oncol; 1995; 34(7):975-7. PubMed ID: 7492395
    [No Abstract]   [Full Text] [Related]  

  • 7. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
    Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
    Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine.
    Sommer HH; Fosså SD; Lien HH
    Cancer Chemother Pharmacol; 1985; 14(3):277-8. PubMed ID: 3995687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.
    Murphy BR; Rynard SM; Pennington KL; Grosh W; Loehrer PJ
    Am J Clin Oncol; 1994 Feb; 17(1):10-3. PubMed ID: 8311000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
    Mickisch GH; Noordzij MA; vd Gaast A; Gebreamlack P; Köhrmann KU; Mogler-Drautz E; Kupper H; Schröder FH
    J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R11-6. PubMed ID: 8698736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
    Tai CJ
    Acta Oncol; 2009; 48(6):931-2. PubMed ID: 19925379
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
    Kellokumpu-Lehtinen P; Nordman E
    J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
    Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.
    Rodenburg CJ; Nooter K; Herweijer H; Seynaeve C; Oosterom R; Stoter G; Verweij J
    Ann Oncol; 1991 Apr; 2(4):305-6. PubMed ID: 1868026
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
    Yagoda A
    Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
    Yagoda A; Abi-Rached B; Petrylak D
    Semin Oncol; 1995 Feb; 22(1):42-60. PubMed ID: 7855619
    [No Abstract]   [Full Text] [Related]  

  • 19. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline].
    Kakehi Y; Hashimura T; Yoshida O; Segawa T; Kanematsu A
    Hinyokika Kiyo; 1993 Dec; 39(12):1227-32. PubMed ID: 8285174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.